Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combination iron depletion therapy.

R Taetle1, J M Honeysett, R Bergeron

  • 1Department of Pathology, University of California Cancer Center, San Diego.

Journal of the National Cancer Institute
|August 16, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between personality traits of primiparous dairy cows and their response to prepartum training and subsequent adaptation to an automated milking system.

Journal of dairy science·2026
Same author

Effect of training dairy heifers to an automated milking system before parturition on their adaptation and performance.

Journal of dairy science·2025
Same author

Influence of dairy cow personality traits on response to extended milking intervals and removal of supplemental concentrate in a free-traffic automated milking system.

Journal of dairy science·2025
Same author

Effect of training method and dairy cow personality traits on adaptation to an automated milking system.

Journal of dairy science·2024
Same author

Effect of dairy cow personality traits and concentrate allowance on their response to training and adaptation to an automated milking system.

Journal of dairy science·2024
Same author

Flexible feeding: Dairy cow personality affects changes in feeding behavior and milk production under feed competition conditions.

Journal of dairy science·2023

Iron depletion therapies, including monoclonal antibodies and chelators, show promise for treating tumors. Combination therapies are more effective against sensitive hematopoietic cells than resistant solid tumors, suggesting targeted approaches for specific cancers.

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • Iron (Fe) depletion using anti-transferrin receptor monoclonal antibodies (MAbs), Fe chelators, or gallium (Ga) salts inhibits tumor cell growth.
  • The transferrin receptor is a target for cancer therapies due to its role in iron uptake by rapidly dividing cells.

Purpose of the Study:

  • To investigate the cytotoxic effects of an anti-human transferrin receptor MAb (42/6) in combination with an Fe chelator (parabactin) or Ga nitrate.
  • To determine the differential sensitivity of hematopoietic and solid tumor cells to iron depletion strategies.

Main Methods:

  • In vitro studies using human hematopoietic (HL60 leukemia) and solid tumor (KB carcinoma) cell lines.
  • Treatment with MAb 42/6, parabactin, Ga nitrate, and isoquinaldehyde thiosemicarbazone, individually and in combination.

Related Experiment Videos

  • Cell cycle analysis and assessment of cytotoxicity on normal marrow progenitors.

    • Main Results:

    • Parabactin and MAb 42/6 exhibited similar sensitivity patterns across cell lines, with HL60 cells being more sensitive than KB cells.
    • Combination therapy of MAb 42/6 with parabactin or Ga nitrate enhanced cytotoxicity in MAb 42/6-sensitive HL60 cells but not in resistant KB cells.
    • Iron depletion primarily affected cells in the S phase and G1 phase, with MAb 42/6 increasing parabactin's toxicity to normal hematopoietic progenitors.

    Conclusions:

    • Hematopoietic cells are generally more sensitive to iron depletion than solid tumor cells.
    • Combination iron depletion therapy using MAb 42/6 with Fe chelators or Ga salts is effective against sensitive tumors like HL60 leukemia.
    • Further evaluation of combination iron depletion therapy for hematopoietic cell tumors in vivo is warranted.